Nicorette Mini Return Provides More Retail Therapy For Glaxo Consumer
This article was originally published in The Tan Sheet
Executive Summary
Following the February launch of its Flonase Allergy Relief OTC switch and the return of alli following a recall, Glaxo adds another momentum driver before the pending launch of its consumer product JV with Novartis by returning Nicorette minis as an OTC revenue source.